NonHodgkin's Lymphoma with Peritoneal Localization by E. Curakova, M. Genadieva-Dimitrova, J. Misevski, V. Caloska-Ivanova, V. Andreevski, B. Todorovska, U. Isahi, M. Trajkovska, P. Misevska, N. Joksimovic, S. Genadieva-Stavric, S. Antovic, N. Jankulovski

Get full text

Primary T-Cell Non-Hodgkin Lymphoma of the Vagina by J. L. Herraiz, A. Llueca, Y. Maazouzi, D. Piquer, A. Palmeiro, E. Calpe

“…The primary vaginal T-cell non-Hodgkin lymphoma is a rare form of lymphoma. Most of the previously published cases were about B-cell non-Hodgkin lymphomas. …”
Get full text

Digital Gangrene: An Unusual Manifestation of Non-Hodgkin Lymphoma by Muhammad Shoaib Momen Majumder, Shamim Ahmed, Tajkia Haque, Syed Atiqul Haq, Saumitra Chakravarty, Md. Abu Shahin, Din-E-Mujahid Mohammad Faruque Osmany, Johannes J. Rasker

“…Background. Non-Hodgkin lymphomas (NHLs) comprise a group of haematologic malignancies with different histologic subtypes. …”
Get full text

Anaplastic, T-Cell, Non-Hodgkin's Lymphoma Presenting with Haematuria by C. Blick, S. Abdelhadi, D. Bailey, A. Muneer

“…Non-Hodgkin's lymphoma (NHL) represents about 3% of new cancer cases[1]. …”
Get full text

Monoclonal Antibodies for Non-Hodgkin's Lymphoma: State of the Art and Perspectives by Giulia Motta, Michele Cea, Eva Moran, Federico Carbone, Valeria Augusti, Franco Patrone, Alessio Nencioni

“…The use of monoclonal antibodies in B-cell Non-Hodgkin's lymphomas (NHL) represents the greatest example of these advances, as the introduction of the anti-CD20 antibody rituximab has had a dramatic impact on how we treat this group of diseases today. …”
Get full text

Gene expression profiling in B-cell non-Hodgkin lymphomas by Renas N. Saleem, Ahmed Khudair Yassin

Subjects: “…b-cell non-hodgkin lymphoma…”
Get full text

Use of Rituximab in Autoimmune Hemolytic Anemia Associated with Non-Hodgkin Lymphomas by Claudio Fozza, Maurizio Longinotti

“…The association between non-Hodgkin lymphomas and autoimmune disorders is a well-known event. …”
Get full text

Primary Bilateral Non-Hodgkin's Lymphoma of the Adrenal Gland: A Case Report by Ahmed Amine Bouchikhi, Mohamed fadl Tazi, Driss Amiroune, Soufiane Mellas, Jalaledine El Ammari, Abdelhak Khallouk, Mohammed Jamal El fassi, Moulay Hassan Farih

“…Primary bilateral non-Hodgkin's lymphoma (NHL) of the adrenal gland is a very rare entity. …”
Get full text

AIDS-Related Non-Hodgkin's Lymphoma in the Era of Highly Active Antiretroviral Therapy by Prakash Vishnu, David M. Aboulafia

Get full text

EMAP II Expression Is Increased on Peripheral Blood Cells from Non-Hodgkin Lymphoma by Manal Mohamed Saber

Get full text

Prognostic Significance of Serum Proangiogenic Molecules in Patients with De Novo Non-Hodgkin Lymphomas by Pairaya Rujirojindakul, Arnuparp Lekhakula

“…Serum VEGF and bFGF concentrations were measured from 79 adult patients with newly diagnosed stage 2–4 non-Hodgkin lymphomas by quantitative sandwich enzyme immunoassay. …”
Get full text

B-cell non-Hodgkin's lymphoma in the patient with chronic hepatitis C and mixed cryoglobulinemia by V. S. Adonyeva, Ye. A. Kolodyazhnaya, A. B. Bochkarev

Subjects: Get full text

Impact of Methotrexate and 7‐Hydroxymethotrexate Exposure on Renal Toxicity in Pediatric Non‐Hodgkin Lymphoma by Hao Bing, Yi Ma, Jiamin Xu, Qixian Ling, Yanlong Duan, Libo Zhao

“…Method A total of 280 plasma concentration data (140 for MTX and 140 for 7‐OHMTX) for 60 pediatric patients with non‐Hodgkin lymphoma (NHL) were prospectively collected. …”
Get full text

Ovarian Non-Hodgkin Lymphoma Revealed by Bone Metastasis: A Rare Pediatric Case by M. Elbaz, S. Hiroual, F. Boukis, H. Raiss, A. Matrane, J. Elhoudzi

“…Ovary involvement of non-Hodgkin lymphoma (NHL) is rare. We report a rare case of ovarian NHL during adolescence revealed by bone metastasis. …”
Get full text

Obstructive Jaundice as an Initial Manifestation of Non-Hodgkin Lymphoma: Treatment Dilemma and High Mortality by Dhara Chaudhari, Sarah Khan, Atif Saleem, Tamarro Taylor, Chakradhar Reddy, Thomas Borthwick, Mark Young

“…Introduction. Non Hodgkin lymphoma (NHL) presenting with obstructive jaundice is a rare occurrence. …”
Get full text

Activating the Antitumor Immune Response in Non-Hodgkin Lymphoma Using Immune Checkpoint Inhibitors by Maansi Joshi, Stephen M. Ansell

“…Non-Hodgkin lymphomas comprise a heterogenous group of disorders which differ in biology. …”
Get full text

Incidence, Risk Factors, and Modified Risk Assessment Model of Venous Thromboembolism in Non‐Hodgkin Lymphoma Patients by Wen Li, Rui Liu, Ying Shen, GongZhizi Gao, Rui Yang, Yiwen Wang, Ruoyu Yang, Zujie Lin, Ruijun Dong, Wanhong Zhao, Aili He, Ju Bai

Subjects: “…non‐Hodgkin lymphoma…”
Get full text

Monitoring Disease Progression and Therapeutic Response in a Disseminated Tumor Model for Non-Hodgkin Lymphoma by Bioluminescence Imaging by Margarethe Köberle, Kristin Müller, Manja Kamprad, Friedemann Horn, Markus Scholz

“…Our aim was to establish and apply a model for aggressive CD20-positive B-cell non-Hodgkin lymphomas, enabling us to monitor tumor growth and shrinkage in a noninvasive manner. …”
Get full text

The Feature of Distribution and Clonality of TCR γ/δ Subfamilies T Cells in Patients with B-Cell Non-Hodgkin Lymphoma by Liang Wang, Meng Xu, Chunyan Wang, Lihua Zhu, Junyan Hu, Shaohua Chen, Xiuli Wu, Bo Li, Yangqiu Li

“…To further characterize the γδ T-cell immune status in B-cell non-Hodgkin lymphoma (B-NHL), we investigated the distribution and clonality of TCR Vγ/Vδ repertoire in peripheral blood (PB), bone marrow (BM), and lymph node (LN) from patients with B-NHL. …”
Get full text

Dual-targeting CAR T cells for B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma by Gustavo de Oliveira Canedo, Claire Roddie, Persis J. Amrolia

“…Abstract: Relapse after CD19-directed chimeric antigen receptor (CAR) T-cell therapy remains a major challenge in B-cell acute lymphoblastic leukemia (ALL) and B-cell non-Hodgkin lymphoma (B-NHL). One of the main strategies to avoid CD19-negative relapse has been the development of dual CAR T cells targeting CD19 and an additional target, such as CD22 or CD20. …”
Get full text